Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Valerie Moberg"'
Autor:
Yian Ann Chen, Michael Schell, Xiuhua Zhao, Heather Cronin, Valerie Moberg, Lori McCormick, Allison Richards, Jodie Kroeger, Alberto J. Martinez, Pingyan Cheng, Bin Yu, Ragini Kudchadkar, Geoffrey Gibney, Jeffrey Weber
Gating Strategy for MDSC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a33646293493acc3eb3bcdf47773880
https://doi.org/10.1158/2326-6066.22537871.v1
https://doi.org/10.1158/2326-6066.22537871.v1
Autor:
Yian Ann Chen, Michael Schell, Xiuhua Zhao, Heather Cronin, Valerie Moberg, Lori McCormick, Allison Richards, Jodie Kroeger, Alberto J. Martinez, Pingyan Cheng, Bin Yu, Ragini Kudchadkar, Geoffrey Gibney, Jeffrey Weber
Suppression of T-cell proliferation by MDSC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d09f018d16c61f4fa82c6a50a599120
https://doi.org/10.1158/2326-6066.22537868.v1
https://doi.org/10.1158/2326-6066.22537868.v1
Autor:
Yian Ann Chen, Michael Schell, Xiuhua Zhao, Heather Cronin, Valerie Moberg, Lori McCormick, Allison Richards, Jodie Kroeger, Alberto J. Martinez, Pingyan Cheng, Bin Yu, Ragini Kudchadkar, Geoffrey Gibney, Jeffrey Weber
The checkpoint inhibitor nivolumab is active in patients with metastatic melanoma who have failed ipilimumab. In this phase I/II study, we assessed nivolumab's safety in 92 ipilimumab-refractory patients with unresectable stage III or IV melanoma, in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d7be50ee32acc2c375be484ca0085349
https://doi.org/10.1158/2326-6066.c.6548582.v1
https://doi.org/10.1158/2326-6066.c.6548582.v1
Autor:
Yian Ann Chen, Michael Schell, Xiuhua Zhao, Heather Cronin, Valerie Moberg, Lori McCormick, Allison Richards, Jodie Kroeger, Alberto J. Martinez, Pingyan Cheng, Bin Yu, Ragini Kudchadkar, Geoffrey Gibney, Jeffrey Weber
Supplementary Materials and Methods and Supplementary Table 1. This table describes the treatment characteristics of the six cohorts of patients that participated in the study described herein, including what grades of toxicity to prior ipilimumab th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ef5d952fef9109a3a55d8557be540d3
https://doi.org/10.1158/2326-6066.22537874.v1
https://doi.org/10.1158/2326-6066.22537874.v1
Autor:
Dmitry I. Gabrilovich, Amod A. Sarnaik, Meenhard Herlyn, Jeffrey S. Weber, Gao Zhang, Jiufeng Tan, Min Xiao, Vito W. Rebecca, Jane L. Messina, Michael Schell, Shari Pilon-Thomas, Valerie Moberg, Allison Richards, Laxminarasimha Donthireddy, Sergio Lavilla-Alonso, Taekyoung Kwak, Cigdem Atay
Purpose:BRAF and MEK inhibitors (BRAFi and MEKi) are actively used for the treatment of metastatic melanoma in patients with BRAFV600E mutation in their tumors. However, the development of resistance to BRAFi and MEKi remains a difficult clinical cha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be7b6419a819ee05fd6bc1d0bb7e5d9f
https://doi.org/10.1158/1078-0432.c.6528660
https://doi.org/10.1158/1078-0432.c.6528660
Autor:
Dmitry I. Gabrilovich, Amod A. Sarnaik, Meenhard Herlyn, Jeffrey S. Weber, Gao Zhang, Jiufeng Tan, Min Xiao, Vito W. Rebecca, Jane L. Messina, Michael Schell, Shari Pilon-Thomas, Valerie Moberg, Allison Richards, Laxminarasimha Donthireddy, Sergio Lavilla-Alonso, Taekyoung Kwak, Cigdem Atay
Supplemental Figure 1. Temporal regulation and the effect of combination of B-raf inhibitor on M6PR expression. Supplemental Figure 2. Effect of combination of B-raf and MEK inhibitors on M6PR expression. Supplemental Figure 3. WM35 cells resistant t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93ac9e5a569075a46b74546c554e850a
https://doi.org/10.1158/1078-0432.22474029.v1
https://doi.org/10.1158/1078-0432.22474029.v1
Autor:
Gao Zhang, Shari Pilon-Thomas, Dmitry I. Gabrilovich, Sergio Lavilla-Alonso, Tae Kyoung Kwak, Laxminarasimha Donthireddy, Valerie Moberg, Michael J. Schell, Min Xiao, Cigdem Atay, Vito W. Rebecca, Amod A. Sarnaik, Jeffrey S. Weber, Meenhard Herlyn, Jane L. Messina, Jiufeng Tan, Allison D Richards
Publikováno v:
Clin Cancer Res
Purpose: BRAF and MEK inhibitors (BRAFi and MEKi) are actively used for the treatment of metastatic melanoma in patients with BRAFV600E mutation in their tumors. However, the development of resistance to BRAFi and MEKi remains a difficult clinical ch
Autor:
Valerie Moberg, Xiuhua Zhao, Heather Cronin, Lori McCormick, Yian Ann Chen, Geoffrey T. Gibney, Bin Yu, Michael J. Schell, Ragini R. Kudchadkar, Jeffrey S. Weber, Allison Richards, PingYan Cheng, Jodie Kroeger, Alberto J Martinez
Publikováno v:
Cancer Immunology Research. 4:345-353
The checkpoint inhibitor nivolumab is active in patients with metastatic melanoma who have failed ipilimumab. In this phase I/II study, we assessed nivolumab's safety in 92 ipilimumab-refractory patients with unresectable stage III or IV melanoma, in
Autor:
Tae Kyoung Kwak, Michael J. Schell, Allison Richards, Amod A. Sarnaik, Jane L. Messina, Shari Pilon-Thomas, Cigdem Atay, Jeffrey S. Weber, Meenhard Herlyn, Vito W. Rebecca, Valerie Moberg, Dmitry I. Gabrilovich, Gao Zhang, Sergio Lavilla-Alonso
Publikováno v:
Cancer Immunology Research. 8:B41-B41
Although treatment of combination therapy with BRAF and MEK inhibitors in patient with melanoma has shown longer duration of response and higher rate of tumor responses, recurrence of tumor from dual targeted therapy in patients with metastatic melan